RNAC$7.35
Chart
Performance
Key Stats
AI RNAC Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldCartesian Therapeutics (RNAC) is a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases. The company exhibits potential driven by its lead candidate, Descartes-08, but faces significant risks associated with clinical trial progression, binary outcomes, and substantial cash burn. Its current fundamental and technical outlook presents a mixed picture, warranting a 'Hold' rating.
Thematic
The company operates within the growing biotechnology sector, with a specific focus on mRNA technology and autoimmune disease treatments. While these areas have strong long-term tailwinds, the specific application and stage of development for RNAC's therapies are critical factors.
Fundamental
RNAC's financials show a company with substantial cash reserves for its stage, but also significant operating losses and negative free cash flow. The P/E ratio is not applicable due to negative earnings, and the Price-to-Sales ratio is high, reflecting its early-stage valuation. The company has no dividend yield.
Technical
RNAC's stock price has experienced significant volatility. While short-term momentum indicators show mixed signals, longer-term trends and key moving averages suggest potential upward momentum, though recent performance indicates weakness. The stock has recently seen considerable price swings.
| Factor | Score |
|---|---|
| Biotechnology Sector Growth | 75 |
| Autoimmune Disease Market | 70 |
| Clinical Stage Risk | 40 |
| Regulatory Landscape (Biotech) | 60 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 50 |
| Balance Sheet Health | 80 |
| Cash Flow | 20 |
| Debt Level | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 45 |
| Moving Averages | 60 |
| Volume | 40 |
| Short-Term Performance | 70 |
| Long-Term Performance | 30 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Recent Positive Momentum
The stock price has seen positive performance over multiple short-term periods, with a 5-day performance of +8.62% and a 1-month performance of +23.88%.
Low Price-to-Earnings Ratio
The trailing P/E ratio (PE_TTM) of 2.48 is exceptionally low, suggesting the stock may be significantly undervalued based on its current earnings.
Bearish Points (8)
Significant Long-Term Decline
Despite recent short-term gains, the stock has experienced a significant decline over longer periods, with a 6-month performance of -31.87% and a 1-year performance of -22.99%.
Negative Earnings and High Price-to-Sales
The company has consistently reported negative net income (e.g., -$77.42 million in 2024, -$219.71 million in 2023) and a very high Price-to-Sales ratio (PS) of 471.7 (TTM), indicating a lack of profitability and a speculative valuation.
Calendar
August 2025
14
Next Earnings Date
H: $-0.65
A: $-0.65
L: $-0.65
H: 5.00M
A: 812.50K
0Profile
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.
Seasonals
Price Target
36.43 USD
The 39 analysts offering 1 year price forecasts for RNAC have a max estimate of 42.00 and a min estimate of 16.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in advanced wound care and regenerative medicine, specializing in skin substitutes and biologics for wound healing, which aligns closely with Renovacare's focus.
Weight: 90
Direct competitor in regenerative medicine, specifically developing and commercializing autologous cell therapies for severe burn injuries (skin grafts) and cartilage repair.
Weight: 88
Significant player in regenerative technologies, surgical solutions, and advanced wound care, offering products for skin and tissue repair, making them a direct industry peer.
Weight: 85
Global medical technology company with a major segment dedicated to advanced wound management, surgical reconstruction, and orthopedics, a key competitor in the broader wound care market.